Ion channel inhibitor
Ion channel inhibitor
Search
PD-1 antibody
PD-1 antibody
Vascular modulator
Vascular modulator
Phospholipid modulator
Phospholipid modulator
Lysophospholipase inhibitor
Lysophospholipase inhibitor
Glutamate receptor modulator
Glutamate receptor modulator
Generalized pustular psoriasis: Unmet needs
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
Anti-fibrotic agent
Anti-fibrotic agent
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
VSV-GP
VSV-GP
C3-binding polypeptide
C3-binding polypeptide
Modified yersinia
Modified yersinia
IL11 antibody
IL11 antibody
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
Brigimadlin
MDM2-p53 antagonist
Brigimadlin (BI 907828)
Brigimadlin BI 907828
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
GLP-1/FGF21 agonist
GLP-1/FGF21 agonist
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
SIRPα antagonist
SIRPα antagonist
CD137/FAP agonist
CD137/FAP agonist
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
KRAS multi-inhibitor
KRAS multi-inhibitor
NPY2r agonist
Food intake regulator